Mehrdad E. Alemozaffar

Mehrdad Alemozaffar practices at Kaiser Permanente Los Angeles Medical Center in Los Angeles, California, part of Kaiser Permanente.

Mehrdad Alemozaffar's NPI, 1376749861, was assigned on June 22, 2007. Mehrdad Alemozaffar graduated from David Geffen School of Medicine at UCLA in 2007. Mehrdad Alemozaffar's Georgia license number on file is 072548.

Mehrdad Alemozaffar's primary practice is Kaiser Permanente Los Angeles Medical Center, at 4867 Sunset Blvd, Los Angeles, CA 90027 in Los Angeles County. The practice phone is (323) 783-4011.

Mehrdad Alemozaffar's primary practice is Kaiser Permanente Los Angeles Medical Center in Los Angeles, California, part of Kaiser Permanente. Mehrdad Alemozaffar is also affiliated with Brigham and Women's Hospital. The medical group on file is Southern California Permanente Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Mehrdad Alemozaffar practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Mehrdad Alemozaffar's primary specialty in the NPI Registry, under taxonomy code 208800000X. Mehrdad Alemozaffar is board certified in urology by the American Board of Urology. Dmand AI has Mehrdad Alemozaffar's licenses on file in 3 states: Georgia, California and Massachusetts.

Dmand AI lists UTI among the conditions Mehrdad Alemozaffar treats.

CMS data shows 2,111 Medicare services from Mehrdad Alemozaffar across 14 procedure codes in 2019, for 15 Medicare patients. Medicare paid $58,579 for them.

CMS counts 15 Medicare patients who saw Mehrdad Alemozaffar in 2024. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mehrdad Alemozaffar's median patient age at 70, with 26% women.

In 2024, Mehrdad Alemozaffar wrote 1,011 Medicare Part D claims for 294 patients. 96% of them were for generic drugs. CMS names the drug for 865 of them, across 9 drugs with 11 or more claims each, at $28,257 in total drug cost. In 2023, CMS named 822 claims across 8 drugs.

Mehrdad Alemozaffar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mehrdad Alemozaffar as offering telehealth.

Dmand AI links 36 papers to Mehrdad Alemozaffar, published from 2008 to 2023. 2019 was the busiest year, with 5. The most frequent topics are Prostatectomy, Prostatic Neoplasms and Urinary Bladder Neoplasms. Mehrdad Alemozaffar has published most often in Eur Urol. Mehrdad Alemozaffar's most frequent co-authors are Christopher Paul Filson, MD, MS, Mehmet Asim Bilen, MD and Jim C. Hu, MD, MPH.

Dmand AI links Mehrdad Alemozaffar to 1 clinical trial. Conditions studied include Neoplasm Metastasis and Neoplastic Processes.

CMS Open Payments shows 156 general payments to Mehrdad Alemozaffar from 13 drug and device companies from 2016 to 2025. Education make up the largest share, 52% of the total. Intuitive Surgical, Inc. paid the most, $88,342.

Mehrdad Alemozaffar graduated from David Geffen School of Medicine at UCLA in 2007.

Mehrdad Alemozaffar is in network with 4 carriers, including Excellus BlueCross BlueShield, Kaiser Permanente and CMS Medicare. EPO plans come from the most carriers, 2. Check the plan with the practice before a visit.